ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 143 filers reported holding ASCENDIS PHARMA A/S in Q1 2019. The put-call ratio across all filers is 0.49 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $2,885,000 | -71.7% | 18,100 | -76.6% | 0.13% | -69.8% |
Q2 2021 | $10,189,000 | -2.9% | 77,450 | -4.9% | 0.42% | -5.4% |
Q1 2021 | $10,497,000 | -34.1% | 81,450 | -14.7% | 0.44% | -40.3% |
Q4 2020 | $15,919,000 | -10.6% | 95,450 | -17.3% | 0.74% | -13.4% |
Q3 2020 | $17,816,000 | -7.7% | 115,450 | -11.5% | 0.86% | +3.7% |
Q2 2020 | $19,294,000 | +13.9% | 130,450 | -13.3% | 0.83% | +7.0% |
Q1 2020 | $16,942,000 | -55.0% | 150,450 | -44.4% | 0.78% | -41.7% |
Q4 2019 | $37,625,000 | +25.8% | 270,450 | -12.9% | 1.33% | +30.4% |
Q3 2019 | $29,903,000 | -66.2% | 310,450 | -59.6% | 1.02% | -62.2% |
Q2 2019 | $88,457,000 | -25.5% | 768,193 | -23.8% | 2.70% | -19.0% |
Q1 2019 | $118,664,000 | +87.9% | 1,008,193 | 0.0% | 3.33% | +59.8% |
Q4 2018 | $63,163,000 | +13.3% | 1,008,193 | +28.2% | 2.08% | +13.1% |
Q3 2018 | $55,731,000 | +86.0% | 786,493 | +74.6% | 1.84% | +86.0% |
Q2 2018 | $29,969,000 | – | 450,526 | – | 0.99% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |